CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma.
about
Elotuzumab: the first approved monoclonal antibody for multiple myeloma treatmentElotuzumab for the treatment of multiple myelomaNovel cancer antigens for personalized immunotherapies: latest evidence and clinical potentialMonoclonal antibodies in the treatment of multiple myeloma: current status and future perspectivesSpotlight on elotuzumab in the treatment of multiple myeloma: the evidence to dateTreatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumabThe role of SLAMF7 in multiple myeloma: impact on therapy.Elotuzumab: a novel immune-stimulating therapy to treat multiple myeloma.Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathwaysProfile of elotuzumab and its potential in the treatment of multiple myelomaThe development of potential antibody-based therapies for myelomaCombination immune therapies to enhance anti-tumor responses by NK cells.Immune oppression array elucidating immune escape and survival mechanisms in uveal melanoma.Preclinical and clinical evaluation of elotuzumab, a SLAMF7-targeted humanized monoclonal antibody in development for multiple myeloma.Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma.Novel Immunotherapies for Multiple Myeloma.Evaluation of B cell maturation antigen as a target for antibody drug conjugate mediated cytotoxicity in multiple myeloma.Efficacy and safety of elotuzumab for the treatment of multiple myeloma.Emerging Treatment Models in Rheumatology: IgG4-Related Disease: Insights Into Human Immunology and Targeted Therapies.Standardisation of minimal residual disease in multiple myeloma.SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin.Clonal expansion of CD4(+) cytotoxic T lymphocytes in patients with IgG4-related disease.Innate immune activating ligand SUMOylation affects tumor cell recognition by NK cells.Immune cell inhibition by SLAMF7 is mediated by a mechanism requiring src kinases, CD45, and SHIP-1 that is defective in multiple myeloma cells.A review discussing elotuzumab and its use in the second-line plus treatment of multiple myeloma.Multiple myeloma: New surface antigens for the characterization of plasma cells in the era of novel agents.Mechanisms of Action and Clinical Development of Elotuzumab.Diagnosis of Plasma Cell Dyscrasias and Monitoring of Minimal Residual Disease by Multiparametric Flow Cytometry.Myeloproliferative leukemia protein activation directly induces fibrocyte differentiation to cause myelofibrosis.Antibody dependent cellular phagocytosis by macrophages is a novel mechanism of action of elotuzumab.Effect of dietary restriction and subsequent re-alimentation on the transcriptional profile of bovine jejunal epithelium.Model-based pharmacokinetic analysis of elotuzumab in patients with relapsed/refractory multiple myeloma.Antibody based immunotherapy for multiple myeloma: it's about time.A CS1-NKG2D bispecific antibody collectively activates cytolytic immune cells against multiple myeloma.Elotuzumab for the Treatment of Relapsed or Refractory Multiple Myeloma, with Special Reference to its Modes of Action and SLAMF7 Signaling.The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and -independent mechanisms.Coexistence of leishmaniasis and multiple myeloma in the era of monoclonal antibody (anti-CD38 or anti-SLAMF7) containing triplets: one shared story of two exceptional casesClinical impact of serum soluble SLAMF7 in multiple myeloma
P2860
Q26738944-1864171A-71FC-4941-983A-BE63E27CDB13Q26740278-84D6AF0C-B3A7-44E1-B59B-F8B0509AB540Q26769884-8CCB1D7A-78EE-43F9-B4EE-B27573FC1848Q26799104-A918F67C-064B-48C0-987B-F9B59F66078CQ28076147-E27C218C-8B23-477B-8D60-79279241033DQ28078993-A274AA66-8FCA-42A0-8AD0-AFD9074BB95FQ30249167-5EDB0163-5049-4648-8370-AF4B5DE098E2Q30249513-169CE0EA-4B9A-45E5-B921-F8FB459D1A48Q34807860-5743836E-A297-4B21-9B32-FFB93CB36A60Q35628678-9D2C7268-71AC-4A1B-BFDB-744699E2234AQ35788245-4FA3EEC5-4A56-45BA-8B2C-3D1511317C6CQ37408550-DF4140D9-9AFA-45CF-A6BC-FB9A7800562BQ37500476-AC180E4F-B5B6-44B2-BABA-E7B6F5186B83Q38526452-56A38F40-891C-41AF-B1C2-EB3A5009F5E9Q38534837-A96B8352-4763-41E7-AFD0-D79566F88493Q38640444-892E2E0A-805B-415C-86F8-7D44638AB557Q38764001-7B5E82BF-2A3E-4058-B4F0-6627D881BF09Q39070515-D3E79E3C-E508-48BA-BB7B-4EFAEB5FDF4AQ39346488-D67D55D7-15FA-4434-8121-81DDD71D3A79Q39410899-1CFFFC3B-4CA9-4B29-9C2C-EA6799AF796AQ40244852-7C98D352-A265-443B-8265-492A99695FAEQ41036265-50B3717C-2C91-446C-A508-17911CC11F5BQ41620482-B7BC3EB0-1041-47CB-BD00-9397C407A9BFQ43107156-3E749457-425F-4909-AE45-500531B0C251Q47865755-F6BCE5A8-380F-4EB0-925B-5705D839FC9AQ48958626-C530F400-BBBB-44FA-8569-267E0AEB9124Q49615618-26550C91-A5A7-4C09-84C5-23B1BDC8F444Q49641900-68BEA9E1-1F33-405F-8E41-9A48668B418FQ51068295-D71493FE-E693-4A45-926F-425502415763Q52589219-DAAB2450-0453-456A-9FF1-94AF51B1DE6AQ52648796-5AA8D954-15CF-47AE-A021-56C12A926EB9Q53145160-42E504FD-6453-454C-A7FF-6526B968A946Q53349911-9DAE3A27-B53B-4B1C-AA46-989CB83474A0Q54978920-61CDECAD-E6F8-478B-B180-F9B6E7681605Q55310350-8754D4CF-7DC9-44CC-B9E0-8D2BAD105BBBQ55409204-7520AF6B-95EC-4670-9F08-CC020966DD1FQ57904139-7AF5C625-1C5D-499C-9167-DBDB75896D27Q58582611-9986E16A-EA2A-4E12-BF3A-7E3A69BA7FAE
P2860
CS1, a SLAM family receptor involved in immune regulation, is a therapeutic target in multiple myeloma.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
CS1, a SLAM family receptor in ...... ic target in multiple myeloma.
@en
type
label
CS1, a SLAM family receptor in ...... ic target in multiple myeloma.
@en
prefLabel
CS1, a SLAM family receptor in ...... ic target in multiple myeloma.
@en
P1476
CS1, a SLAM family receptor in ...... ic target in multiple myeloma.
@en
P2093
André Veillette
Huaijian Guo
P304
P356
10.1016/J.CRITREVONC.2013.04.003
P577
2013-06-02T00:00:00Z